Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative

Jennifer L. Caswell-Jin*, Anjali D. Zimmer*, Will Stedden, Kerry E. Kingham, Alicia Y. Zhou†, Allison W. Kurian†

See the Notes section for the full list of authors’ affiliations.

Correspondence to: Allison W. Kurian, MD, MSc, Departments of Medicine and Health Research & Policy, Women’s Clinical Cancer Genetics Program, Stanford University School of Medicine, HRP Redwood Building, Room T254A, 150 Governor’s Lane, Stanford, CA 94305-5405 (e-mail: akurian@stanford.edu).

*Co-first authors.
†Co-senior authors.

Abstract

In cascade testing, genetic testing for an identified familial pathogenic variant extends to disease-free relatives to allow genetically targeted disease prevention. We evaluated the results of an online initiative in which carriers of 1 of 30 cancer-associated genes, or their first-degree relatives, could offer low-cost testing to at-risk first-degree relatives. In the first year, 1101 applicants invited 2280 first-degree relatives to undergo genetic testing. Of invited relatives, 47.5% (95% confidence interval [CI] = 45.5 to 49.6%) underwent genetic testing, and 12.0% (95% CI = 9.2 to 14.8%) who tested positive continued the cascade by inviting additional relatives to test. Of tested relatives, 4.9% (95% CI = 3.8 to 6.1%) had a pathogenic variant in a different gene from the known familial one, and 16.8% (95% CI = 14.7 to 18.8%) had a variant of uncertain significance. These results suggest that an online, low-cost program is an effective approach to implementing cascade testing, and that up to 5% of the general population may carry a pathogenic variant in 1 of 30 cancer-associated genes.

Testing those diagnosed with a disease is the most efficient way to identify carriers of predisposing germline genetic variants, and is consistent with clinical practice guidelines (1). To achieve the goal of genetically targeted primary disease prevention, testing for an identified familial pathogenic variant must then extend to disease-free relatives in a process known as “cascade testing” (2–4). Cascade testing has been designated by the Centers for Disease Control and Prevention as a Tier 1 genomic application for Lynch Syndrome and Hereditary Breast and Ovarian Cancer Syndrome (5). However, there are major barriers to cascade testing, including cost, insurance constraints (6), and confidentiality laws that prohibit direct contact of a patient’s relatives by her/his physician or genetic counselor. The burden of informing relatives about test results and their implications falls primarily on the patient, who may simultaneously be struggling with a new diagnosis (7). In the cancer genetics field, technologic advances have reduced testing costs and enabled new care delivery models (8,9). We evaluated the first year of an online, low-cost family testing initiative offered by a testing laboratory.

People with a previously identified pathogenic variant (“carriers”) detected by any Clinical Laboratory Improvements Amendment (CLIA)-certified laboratory in one of 30 cancer-associated genes (Supplementary Table 1, available online), or their first-degree relatives (FDRs), could apply to the family testing program (Figure 1A). People with a qualifying pathogenic result from the testing laboratory received an email introducing the family testing program; information about the program was also distributed to potential participants with the results from other laboratories through online advertisements, at clinics, and at events for families with hereditary cancer. After initial application, the testing laboratory sent emails to FDRs identified by the applicant, inviting them to undergo CLIA-certified multiplex sequencing of these 30 genes at an out-of-pocket cost of US...
$50. Sequencing and variant classification followed standard practice guidelines (Supplementary Methods, available online). FDRs with pathogenic results were required to speak by telephone with a genetic counselor to obtain their test results and counseling about cancer risk (10,11). All participants signed informed consent approved by the Western Institutional Review Board, Inc. All P-values are two-sided, and a $P$-value of less than .05 was considered statistically significant.

In the program’s first year (September 27, 2016 to September 27, 2017), 1101 applicants (741 carriers and 360 FDRs) invited 2280 FDRs. Applicants were more often women (78.1% of carrier applicants, binomial $P < .001$; 63.9% of FDR applicants, binomial $P < .001$); demographic details are in Supplementary Table 2 (available online). During the follow-up period (median = 216 days), 47.5% (95% CI = 45.5 to 49.6%) of invited FDRs underwent testing. Invited female relatives were more likely to test than males (52.6% vs 42.0%, $\chi^2 P < .001$). There were no differences in testing by gene (Figure 1B): relatives who were invited because of a pathogenic variant associated with a well-characterized syndrome (BRCA1/2, MLH1, MSH2, MSH6, PMS2, CDH1, CDKN2A, STK11, and TP53) were tested as often as those who were invited because of a pathogenic variant in a less well-characterized gene (48.1% vs 45.9%, $\chi^2 P = .31$) (Supplementary Table 2, available online). Among all invited FDRs who tested positive, 12.0% (95% CI = 9.2 to 14.8%) continued the cascade by inviting additional FDRs.

Of FDRs who tested (Figure 2A), 48.1% (95% CI = 45.4 to 50.8%) carried the identified familial pathogenic variant (consistent with their stated first-degree genetic relationship to carriers) and 4.9% (95% CI = 3.8 to 6.1%) a different pathogenic variant. Of these unexpected pathogenic variants, 42.4% (95% CI = 30.5 to 54.3%) were in low-penetrance alleles (specifically APC I1307K, CHEK2 I157T, and MUTYH heterozygotes), 37.9% (95% CI = 26.2 to 49.6%) in less well-characterized cancer risk genes (specifically ATM, BARD1, BRIP1, CHEK2, MITF, NBN, RAD51C, and RAD51D), and 19.7% (95% CI = 10.1 to 29.3%) in syndromic genes (specifically BRC1/2, MLH1, MSH2, MSH6, and PMS2) (Figure 2B). Of tested FDRs, 16.8% (95% CI = 14.7 to 18.8%) had a variant of uncertain significance, and 54.5% (95% CI = 48.0 to 61.1%) of these also had a pathogenic variant.

Cascade testing for cancer susceptibility gene mutations faces substantial challenges. Despite recent cost declines, testing often costs $500 or more and may lack insurance coverage: Medicare does not cover preventive genetic testing of cancer-free relatives. In the US, privacy regulations prohibit direct contact of relatives by patients’ clinicians, which concentrates the burden of informing relatives on carriers themselves. Cascade testing rates in specialized genetics clinics are low, at approximately 30% of eligible FDRs (12–14). Alternative care models that allow direct contact of relatives by patients’ clinicians can improve testing rates to 50 to 60% (12,14), but have not been explored in the US. In the model described here, patients empowered the laboratory to initiate testing by providing FDRs’ email addresses for direct contact. At 47.5%, FDRs’ testing uptake equaled that of the Lynch Syndrome cascade protocols at expert centers (15). However, continued cascade testing beyond one FDR was low (12.0%). Cascade rates beyond the first degree are not described in the existing literature, which has relied on
patient report, and the rate documented here should serve as a benchmark for future studies. While the cascade rate might be expected to decrease with each successive invitation of relatives, the observed drop-off to 12.0% is likely suboptimal. This drop-off could reflect limited understanding of test results, which is the major potential weakness of an online approach without in-person counseling. While FDRs with pathogenic results received posttest genetic counseling by telephone (10,11), pretest counseling was provided only as a video, and informed decision-making outcomes were not measured.

Interestingly, 4.9% of FDRs carried an unexpected pathogenic variant that the carrier applicant did not share. Previous studies estimated that 10 to 20% of patients with breast, colon, or ovarian cancer carry germline cancer susceptibility genes (16–19). Because the FDRs tested here were selected based on their relationship to a carrier of a different pathogenic variant, and not for family or personal history of cancer suggesting the pathogenic variant they were found to carry, their results (outside of the familial pathogenic variant) may approximate those of the general population. Even excluding unexpected mutations in genes with higher prevalence in the Ashkenazi Jewish population (BRCA1, BRCA2, APC I1307K), we estimate that 3.9% (2.9 to 5.0%) of people may carry a pathogenic variant in a cancer susceptibility gene; this estimate may inform discussion about population-wide genetic testing.

Study limitations include selection bias (eg, computer literacy) and missing information on the number of relatives eligible for testing and whether relatives were tested previously. Most important, this study addresses the first step in cascade testing—enhancing identification and testing of at-risk FDRs—but not the essential next steps of engaging FDRs in informed decision-making about options to manage their risk, such as screening or preventive surgery. Future research must explore strategies to extend affordable testing more broadly; to integrate clinician expertise both pre- and posttesting with online approaches like the one described here; and to enable those testing positive to understand their cancer risks and access appropriate risk-reducing interventions.

Funding
This work was supported by Color Genomics and the BRCA Foundation. JLC is supported by a Physician-Scientist Training Award from the Damon Runyon Cancer Research Foundation.

Notes
Affiliations of authors: Department of Medicine (JLC, KEK, AWK) and Department of Health Research & Policy (AWK), Stanford University School of Medicine, Stanford, CA; Department of Scientific Affairs (ADZ, AYZ), Department of Data Science (WS), Color Genomics, Burlingame, CA.

Employees of Color Genomics served as co-investigators in this study and participated in the design of the study, the collection, analysis, and interpretation of the data; the writing of the article; and the decision to submit the article for publication. The BRCA Foundation had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the article; or the decision to submit the article for publication.

Drs Zimmer, Stedden, and Zhou are employed by and own stock in Color Genomics. Dr Kurian has received research funding from Medscape and from a commercial company that develops and sells genetic testing products. The remaining authors have no financial relationships relevant to this article. The authors have no potential conflicts.

References
1. Daly MB, Pilarski R, Berry M, et al. NCCN guidelines insights: Genetic/familial high-risk assessment: breast and ovarian, Version 2.2017. J Natl Compr Canc Netw. 2017;15(1):9–20.
2. Samimi G, Bernardini MQ, Brody LC, et al. Traceback: A proposed framework to increase identification and genetic counseling of BRCA1 and BRCA2 mutation carriers through family-based outreach. J Clin Oncol. 2017;35(20):2329–2337.
3. Louter L, Defesche J, Roeters van Lennep J. Cascade screening for familial hypercholesterolemia: Practical consequences. Atheroscler Suppl. 2017;30:77–85.
4. Knowles JW, Rader DJ, Khoury MJ. Cascade screening for familial hypercholesterolemia and the use of genetic testing. JAMA. 2017;318(4):381–382.
5. George R, Kovak K, Cox SL. Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases. J Genet Couns. 2015;24(3):388–399.
6. Whitworth P, Beitsch P, Arnell C, et al. Impact of payer constraints on access to genetic testing. J Oncol Pract. 2017;13(1):e47–e56.
7. Katz SJ, Kurian AW, Morrow M. Treatment decision making and genetic testing for breast cancer: Mainstreaming mutations. JAMA. 2015;314(10):997–998.
8. Offit K, Bradbury A, Storm C, et al. Gene patents and personalized cancer care: Impact of the Myriad case on clinical oncology. J Clin Oncol. 2013;31(21):2743–2748.
9. Stadler ZK, Schrader KA, Vijai J, et al. Cancer genomics and inherited risk. J Clin Oncol. 2014;32(7):687–698.
10. Bradbury AR, Patrick-Miller LJ, Egleston BL, et al. Randomized noninferiority trial of telephone vs in-person disclosure of germline cancer genetic test results. J Natl Cancer Inst. 2018;110(9):985–993.
11. Kinney AV, Steffen LE, Brumbach BH, et al. Randomized noninferiority trial of telephone delivery of BRCA1/2 genetic counseling compared with in-person counseling: 1-year follow-Up. J Clin Oncol. 2016;34(24):2914–2924.
12. Sermijn E, Delesie L, Deschepper E, et al. The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: Efficacy and safety. Fam Cancer. 2016;15(2):155–162.
13. Ricker CN, Koff RB, Qu C, et al. Patient communication of cancer genetic test results in a diverse population. Transl Behav Med. 2018;8(1):85–94.
14. Forrest LE, Burke J, Bacic S, et al. Increased genetic counseling support improves communication of genetic information in families. Genet Med. 2008;10(3):167–172.
15. Sharaf RN, Myer P, Stave CD, et al. Uptake of genetic testing by relatives of Lynch syndrome probands: A systematic review. Clin Gastroenterol Hepatol. 2013;11(9):1093–1100.
16. Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2(4):482–490.
17. Tung N, Lin NJ, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460–1468.
18. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304–311.
19. Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol. 2017;35(10):1086–1095.